DexCom price target raised to $140 from $138 at Raymond James

Raymond James analyst Jayson Bedford raised the firm’s price target on DexCom to $140 from $138 and keeps a Strong Buy rating on the shares. DexCom’s Q1 revenue beat expectations by 4%, with better margins, and revenue growth guidance for FY23 was raised by more than the Q1 beat, partly reflecting the earlier implementation of basal reimbursement, the analyst tells investors in a research note.